A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABSK112 in Patients With Non-Small Cell Lung Cancer
Clinical trial NCT06225804 · RECRUITING
Trial details
- NCT number
- NCT06225804
- Sponsor
- Abbisko Therapeutics Co, Ltd
- Status
- RECRUITING
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2024-02-22
- Primary completion
- 2027-03-01
- Enrollment
- 164
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.